{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:24:25Z","timestamp":1789907065798,"version":"4.0.1"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40257-025-00957-5","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T06:14:25Z","timestamp":1750659265000},"page":"733-745","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Tumor-Infiltrating Lymphocyte Therapy for the Treatment of Metastatic Melanoma"],"prefix":"10.1007","volume":"26","author":[{"given":"Katy K.","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3715-5236","authenticated-orcid":false,"given":"Krishna V.","family":"Komanduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"issue":"2","key":"957_CR1","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.coi.2009.03.002","volume":"21","author":"SA Rosenberg","year":"2009","unstructured":"Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 2009;21(2):233\u201340. https:\/\/doi.org\/10.1016\/j.coi.2009.03.002.","journal-title":"Curr Opin Immunol"},{"issue":"7","key":"957_CR2","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1084\/jem.20050732","volume":"202","author":"L Gattinoni","year":"2005","unstructured":"Gattinoni L, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005;202(7):907\u201312. https:\/\/doi.org\/10.1084\/jem.20050732.","journal-title":"J Exp Med"},{"issue":"11","key":"957_CR3","doi-asserted-by":"publisher","first-page":"4544","DOI":"10.4049\/jimmunol.1600219","volume":"196","author":"SM Anthony","year":"2016","unstructured":"Anthony SM, Rivas SC, Colpitts SL, Howard ME, Stonier SW, Schluns KS. Inflammatory signals regulate IL-15 in response to lymphodepletion. J Immunol (Baltimore MD) 1950. 2016;196(11):4544\u201352. https:\/\/doi.org\/10.4049\/jimmunol.1600219.","journal-title":"J Immunol (Baltimore MD) 1950."},{"issue":"280","key":"957_CR4","doi-asserted-by":"publisher","first-page":"280ps7","DOI":"10.1126\/scitranslmed.aaa3643","volume":"7","author":"CH June","year":"2015","unstructured":"June CH, Riddell SR, Schumacher TN. Adoptive cellular therapy: a race to the finish line. Sci Transl Med. 2015;7(280):280ps7. https:\/\/doi.org\/10.1126\/scitranslmed.aaa3643.","journal-title":"Sci Transl Med."},{"issue":"4770","key":"957_CR5","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.3489291","volume":"233","author":"SA Rosenberg","year":"1986","unstructured":"Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233(4770):1318\u201321. https:\/\/doi.org\/10.1126\/science.3489291.","journal-title":"Science"},{"issue":"1","key":"957_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","volume":"12","author":"F Marofi","year":"2021","unstructured":"Marofi F, et al. CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res Ther. 2021;12(1):81. https:\/\/doi.org\/10.1186\/s13287-020-02128-1.","journal-title":"Stem Cell Res Ther"},{"issue":"3","key":"957_CR7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41571-023-00848-w","volume":"21","author":"S Klobuch","year":"2024","unstructured":"Klobuch S, Seijkens TTP, Schumacher TN, Haanen JBAG. Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma. Nat Rev Clin Oncol. 2024;21(3):173\u201384. https:\/\/doi.org\/10.1038\/s41571-023-00848-w.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"957_CR8","doi-asserted-by":"publisher","first-page":"5117","DOI":"10.4049\/jimmunol.1501657","volume":"195","author":"S Ilyas","year":"2015","unstructured":"Ilyas S, Yang JC. Landscape of tumor antigens in T cell immunotherapy. J Immunol (Baltimore MD) 1950. 2015;195(11):5117\u201322. https:\/\/doi.org\/10.4049\/jimmunol.1501657.","journal-title":"J Immunol (Baltimore MD) 1950."},{"issue":"1","key":"957_CR9","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1038\/s41467-022-33720-z","volume":"13","author":"J Huuhtanen","year":"2022","unstructured":"Huuhtanen J, et al. Evolution and modulation of antigen-specific T cell responses in melanoma patients. Nat Commun. 2022;13(1):5988. https:\/\/doi.org\/10.1038\/s41467-022-33720-z.","journal-title":"Nat Commun"},{"issue":"3","key":"957_CR10","first-page":"705","volume":"29","author":"WH Clark","year":"1969","unstructured":"Clark WH, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969;29(3):705\u201327.","journal-title":"Cancer Res"},{"issue":"24","key":"957_CR11","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1093\/jnci\/81.24.1893","volume":"81","author":"WH Clark","year":"1989","unstructured":"Clark WH, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;81(24):1893\u2013904. https:\/\/doi.org\/10.1093\/jnci\/81.24.1893.","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"957_CR12","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5","volume":"77","author":"CG Clemente","year":"1996","unstructured":"Clemente CG, Mihm MC, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996;77(7):1303\u201310. https:\/\/doi.org\/10.1002\/(SICI)1097-0142(19960401)77:7%3c1303::AID-CNCR12%3e3.0.CO;2-5.","journal-title":"Cancer"},{"issue":"21","key":"957_CR13","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1200\/JCO.2011.37.8539","volume":"30","author":"F Azimi","year":"2012","unstructured":"Azimi F, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol. 2012;30(21):2678\u201383. https:\/\/doi.org\/10.1200\/JCO.2011.37.8539.","journal-title":"J Clin Oncol"},{"issue":"1","key":"957_CR14","first-page":"43","volume":"74","author":"MC Mihm","year":"1996","unstructured":"Mihm MC, Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Investig J Tech Methods Pathol. 1996;74(1):43\u20137.","journal-title":"Lab Investig J Tech Methods Pathol."},{"issue":"2","key":"957_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.pathol.2015.12.006","volume":"48","author":"N Lee","year":"2016","unstructured":"Lee N, Zakka LR, Mihm MC, Schatton T. Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. Pathology (Phila). 2016;48(2):177\u201387. https:\/\/doi.org\/10.1016\/j.pathol.2015.12.006.","journal-title":"Pathology (Phila)"},{"issue":"23","key":"957_CR16","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","volume":"313","author":"SA Rosenberg","year":"1985","unstructured":"Rosenberg SA, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313(23):1485\u201392. https:\/\/doi.org\/10.1056\/NEJM198512053132327.","journal-title":"N Engl J Med"},{"issue":"5","key":"957_CR17","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1200\/JCO.1988.6.5.839","volume":"6","author":"SL Topalian","year":"1988","unstructured":"Topalian SL, et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol. 1988;6(5):839\u201353. https:\/\/doi.org\/10.1200\/JCO.1988.6.5.839.","journal-title":"J Clin Oncol"},{"issue":"25","key":"957_CR18","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","volume":"319","author":"SA Rosenberg","year":"1988","unstructured":"Rosenberg SA, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med. 1988;319(25):1676\u201380. https:\/\/doi.org\/10.1056\/NEJM198812223192527.","journal-title":"N Engl J Med"},{"issue":"15","key":"957_CR19","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1093\/jnci\/86.15.1159","volume":"86","author":"SA Rosenberg","year":"1994","unstructured":"Rosenberg SA, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994;86(15):1159\u201366. https:\/\/doi.org\/10.1093\/jnci\/86.15.1159.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"957_CR20","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/01.CJI.0000016820.36510.89","volume":"25","author":"ME Dudley","year":"1997","unstructured":"Dudley ME, et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother. 1997;25(3):243. https:\/\/doi.org\/10.1097\/01.CJI.0000016820.36510.89.","journal-title":"J Immunother"},{"issue":"32","key":"957_CR21","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","volume":"26","author":"ME Dudley","year":"2008","unstructured":"Dudley ME, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26(32):5233\u20139. https:\/\/doi.org\/10.1200\/JCO.2008.16.5449.","journal-title":"J Clin Oncol"},{"issue":"13","key":"957_CR22","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","volume":"17","author":"SA Rosenberg","year":"2011","unstructured":"Rosenberg SA, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0116.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"957_CR23","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/1479-5876-10-169","volume":"10","author":"E Ellebaek","year":"2012","unstructured":"Ellebaek E, et al. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose interleukin-2 in metastatic melanoma patients. J Transl Med. 2012;10(1):169. https:\/\/doi.org\/10.1186\/1479-5876-10-169.","journal-title":"J Transl Med"},{"issue":"8","key":"957_CR24","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/CJI.0b013e31826e8f5f","volume":"35","author":"S Pilon-Thomas","year":"2012","unstructured":"Pilon-Thomas S, et al. Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother. 2012;35(8):615\u201320. https:\/\/doi.org\/10.1097\/CJI.0b013e31826e8f5f.","journal-title":"J Immunother"},{"issue":"15","key":"957_CR25","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-15-1879","volume":"22","author":"R Andersen","year":"2016","unstructured":"Andersen R, et al. Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen. Clin Cancer Res. 2016;22(15):3734\u201345. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1879.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"957_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000848","volume":"8","author":"JH van den Berg","year":"2020","unstructured":"van den Berg JH, et al. Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up. J Immunother Cancer. 2020;8(2): e000848. https:\/\/doi.org\/10.1136\/jitc-2020-000848.","journal-title":"J Immunother Cancer"},{"issue":"6892","key":"957_CR27","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949\u201354. https:\/\/doi.org\/10.1038\/nature00766.","journal-title":"Nature"},{"issue":"2","key":"957_CR28","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1200\/JCO.22.01763","volume":"41","author":"MB Atkins","year":"2023","unstructured":"Atkins MB, et al. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023;41(2):186\u201397. https:\/\/doi.org\/10.1200\/JCO.22.01763.","journal-title":"J Clin Oncol"},{"issue":"16","key":"957_CR29","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2018","unstructured":"Larkin J, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2018;381(16):1535\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1910836.","journal-title":"N Engl J Med"},{"issue":"1","key":"957_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","volume":"392","author":"JD Wolchok","year":"2025","unstructured":"Wolchok JD, et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2025;392(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa2407417.","journal-title":"N Engl J Med"},{"issue":"12","key":"957_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"J Chesney","year":"2022","unstructured":"Chesney J, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022;10(12): e005755. https:\/\/doi.org\/10.1136\/jitc-2022-005755.","journal-title":"J Immunother Cancer"},{"issue":"24","key":"957_CR32","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1200\/JCO.21.00612","volume":"39","author":"AA Sarnaik","year":"2021","unstructured":"Sarnaik AA, et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J Clin Oncol. 2021;39(24):2656\u201366. https:\/\/doi.org\/10.1200\/JCO.21.00612.","journal-title":"J Clin Oncol"},{"key":"957_CR33","unstructured":"US FDA. FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma. 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-lifileucel-unresectable-or-metastatic-melanoma. Accessed 12 Jan 2025."},{"key":"957_CR34","unstructured":"US FDA. Amtagvi. 2024. https:\/\/www.fda.gov\/vaccines-blood-biologics\/approved-blood-products\/amtagvi. Accessed 12 Jan 2025."},{"issue":"23","key":"957_CR35","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","volume":"387","author":"MW Rohaan","year":"2022","unstructured":"Rohaan MW, et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N Engl J Med. 2022;387(23):2113\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2210233.","journal-title":"N Engl J Med"},{"issue":"8","key":"957_CR36","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi HA, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379(8):722\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1805453.","journal-title":"N Engl J Med"},{"issue":"12","key":"957_CR37","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/S1470-2045(21)00545-3","volume":"22","author":"HA Tawbi","year":"2021","unstructured":"Tawbi HA, et al. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol. 2021;22(12):1692\u2013704. https:\/\/doi.org\/10.1016\/S1470-2045(21)00545-3.","journal-title":"Lancet Oncol"},{"issue":"1","key":"957_CR38","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/00002371-200201000-00009","volume":"25","author":"LM Guirguis","year":"2002","unstructured":"Guirguis LM, et al. Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. J Immunother. 2002;25(1):82.","journal-title":"J Immunother"},{"issue":"5","key":"957_CR39","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/CJI.0000000000000223","volume":"41","author":"GU Mehta","year":"2018","unstructured":"Mehta GU, et al. Outcomes of adoptive cell transfer with tumor-infiltrating lymphocytes for metastatic melanoma patients with and without brain metastases. J Immunother (Hagerstown MD) 1997. 2018;41(5):241\u20137. https:\/\/doi.org\/10.1097\/CJI.0000000000000223.","journal-title":"J Immunother. (Hagerstown MD) 1997"},{"issue":"16_Suppl.","key":"957_CR40","doi-asserted-by":"publisher","first-page":"TPS9606","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS9606","volume":"41","author":"A Betof Warner","year":"2023","unstructured":"Betof Warner A, et al. A pilot trial of autologous tumor infiltrating lymphocytes (lifileucel, LN-144) for patients with asymptomatic melanoma brain metastases. J Clin Oncol. 2023;41(16_Suppl.):TPS9606. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS9606.","journal-title":"J Clin Oncol"},{"issue":"21","key":"957_CR41","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1002\/cncr.30259","volume":"122","author":"AN Shoushtari","year":"2016","unstructured":"Shoushtari AN, et al. The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer. 2016;122(21):3354\u201362. https:\/\/doi.org\/10.1002\/cncr.30259.","journal-title":"Cancer"},{"issue":"21","key":"957_CR42","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1002\/cncr.30258","volume":"122","author":"AP Algazi","year":"2016","unstructured":"Algazi AP, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016;122(21):3344\u201353. https:\/\/doi.org\/10.1002\/cncr.30258.","journal-title":"Cancer"},{"issue":"6","key":"957_CR43","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1200\/JCO.20.00605","volume":"39","author":"MS Pelster","year":"2021","unstructured":"Pelster MS, et al. Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study. J Clin Oncol. 2021;39(6):599\u2013607. https:\/\/doi.org\/10.1200\/JCO.20.00605.","journal-title":"J Clin Oncol"},{"key":"957_CR44","doi-asserted-by":"publisher","first-page":"S654","DOI":"10.1016\/j.annonc.2023.09.2220","volume":"34","author":"G-U Grigoleit","year":"2023","unstructured":"Grigoleit G-U, et al. 1086MO Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced mucosal melanoma after progression on immune checkpoint inhibitors (ICI): results from the phase II C-144-01 study. Ann Oncol. 2023;34:S654. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.2220.","journal-title":"Ann Oncol"},{"issue":"13","key":"957_CR45","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1002\/cncr.31284","volume":"124","author":"KK Tsai","year":"2018","unstructured":"Tsai KK, Bollin KB, Patel SP. Obstacles to improving outcomes in the treatment of uveal melanoma. Cancer. 2018;124(13):2693\u2013703. https:\/\/doi.org\/10.1002\/cncr.31284.","journal-title":"Cancer"},{"issue":"13","key":"957_CR46","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","volume":"385","author":"P Nathan","year":"2021","unstructured":"Nathan P, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385(13):1196\u2013206. https:\/\/doi.org\/10.1056\/NEJMoa2103485.","journal-title":"N Engl J Med"},{"issue":"24","key":"957_CR47","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","volume":"389","author":"JC Hassel","year":"2023","unstructured":"Hassel JC, et al. Three-year overall survival with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2023;389(24):2256\u201366. https:\/\/doi.org\/10.1056\/NEJMoa2304753.","journal-title":"N Engl J Med"},{"issue":"1","key":"957_CR48","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1038\/s41467-024-46906-4","volume":"15","author":"S Leonard-Murali","year":"2025","unstructured":"Leonard-Murali S, et al. Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility. Nat Commun. 2025;15(1):2863. https:\/\/doi.org\/10.1038\/s41467-024-46906-4.","journal-title":"Nat Commun"},{"issue":"2","key":"957_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2022.100132","volume":"2","author":"G Gezgin","year":"2022","unstructured":"Gezgin G, et al. Tumor-infiltrating T cells can be expanded successfully from primary uveal melanoma after separation from their tumor environment. Ophthalmol Sci. 2022;2(2): 100132. https:\/\/doi.org\/10.1016\/j.xops.2022.100132.","journal-title":"Ophthalmol Sci."},{"issue":"16_Suppl.","key":"957_CR50","doi-asserted-by":"publisher","first-page":"9513","DOI":"10.1200\/JCO.2023.41.16_suppl.9513","volume":"41","author":"SP Patel","year":"2023","unstructured":"Patel SP, et al. Tumor infiltrating lymphocyte (TIL) harvest and ex vivo expansion from primary and metastatic (met) uveal melanoma (UM) tumors. J Clin Oncol. 2023;41(16_Suppl.):9513. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.9513.","journal-title":"J Clin Oncol"},{"issue":"2","key":"957_CR51","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008735","volume":"12","author":"AB Warner","year":"2024","unstructured":"Warner AB, et al. Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy. J Immunother Cancer. 2024;12(2): e008735. https:\/\/doi.org\/10.1136\/jitc-2023-008735.","journal-title":"J Immunother Cancer"},{"issue":"Suppl._1","key":"957_CR52","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1182\/blood-2019-129328","volume":"134","author":"B George","year":"2019","unstructured":"George B, et al. Fludarabine and cyclophosphamide based conditioning is associated with good outcomes in patients undergoing matched sibling donor transplants for aplastic anaemia. Blood. 2019;134(Suppl._1):3272. https:\/\/doi.org\/10.1182\/blood-2019-129328.","journal-title":"Blood"},{"issue":"5","key":"957_CR53","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001743","volume":"9","author":"A Nissani","year":"2021","unstructured":"Nissani A, et al. Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy. J Immunother Cancer. 2021;9(5): e001743. https:\/\/doi.org\/10.1136\/jitc-2020-001743.","journal-title":"J Immunother Cancer"},{"key":"957_CR54","unstructured":"US FDA. Proleukin\u00ae (aldesleukin). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103293s5130lbl.pdf. Accessed 7 Jan 2025."},{"key":"957_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2022.100140","author":"JC Hassel","year":"2022","unstructured":"Hassel JC, et al. 35MO Number of IL-2 doses and clinical outcomes of tumor-infiltrating lymphocyte (TIL) cell therapy: post hoc analysis of the C-144-01 trial of lifileucel in patients with advanced melanoma. Immuno-Oncol Technol. 2022. https:\/\/doi.org\/10.1016\/j.iotech.2022.100140.","journal-title":"Immuno-Oncol Technol."},{"key":"957_CR56","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.0105-2896.2006.00382.x","volume":"211","author":"MF Mescher","year":"2006","unstructured":"Mescher MF, et al. Signals required for programming effector and memory development by CD8+ T cells. Immunol Rev. 2006;211:81\u201392. https:\/\/doi.org\/10.1111\/j.0105-2896.2006.00382.x.","journal-title":"Immunol Rev"},{"issue":"10","key":"957_CR57","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-22-1922","volume":"29","author":"A Betof Warner","year":"2023","unstructured":"Betof Warner A, Corrie PG, Hamid O. Tumor-infiltrating lymphocyte therapy in melanoma: facts to the future. Clin Cancer Res. 2023;29(10):1835\u201354. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1922.","journal-title":"Clin Cancer Res"},{"key":"957_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107318","volume":"91","author":"S Zhang","year":"2021","unstructured":"Zhang S, Zhao J, Bai X, Handley M, Shan F. Biological effects of IL-15 on immune cells and its potential for the treatment of cancer. Int Immunopharmacol. 2021;91: 107318. https:\/\/doi.org\/10.1016\/j.intimp.2020.107318.","journal-title":"Int Immunopharmacol"},{"issue":"16_Suppl.","key":"957_CR59","doi-asserted-by":"publisher","first-page":"9515","DOI":"10.1200\/JCO.2024.42.16_suppl.9515","volume":"42","author":"RN Amaria","year":"2024","unstructured":"Amaria RN, et al. OBX-115, an interleukin 2 (IL2)-sparing engineered tumor-infiltrating lymphocyte (TIL) cell therapy, in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma. J Clin Oncol. 2024;42(16_Suppl.):9515. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.9515.","journal-title":"J Clin Oncol"},{"issue":"16_Suppl.","key":"957_CR60","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1200\/JCO.2024.42.16_suppl.2547","volume":"42","author":"Z Han","year":"2024","unstructured":"Han Z, et al. Exploring the safety and efficacy of GT201 as a first-in-class autologous tumor-infiltrating lymphocyte monotherapy in advanced solid tumors. J Clin Oncol. 2024;42(16_Suppl.):2547. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.2547.","journal-title":"J Clin Oncol"},{"issue":"16_Suppl.","key":"957_CR61","doi-asserted-by":"publisher","first-page":"5552","DOI":"10.1200\/JCO.2024.42.16_suppl.5552","volume":"42","author":"J Guo","year":"2024","unstructured":"Guo J, et al. A phase I single-arm, open-label trial of engineering tumor-infiltrating lymphocytes with membrane-bound IL-7 for recurrent ovarian cancer. J Clin Oncol. 2024;42(16_Suppl.):5552. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.5552.","journal-title":"J Clin Oncol"},{"key":"957_CR62","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1146\/annurev.iy.13.040195.001343","volume":"13","author":"G Trinchieri","year":"1995","unstructured":"Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol. 1995;13:251\u201376. https:\/\/doi.org\/10.1146\/annurev.iy.13.040195.001343.","journal-title":"Annu Rev Immunol"},{"key":"957_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.952231","volume":"13","author":"Z Jia","year":"2022","unstructured":"Jia Z, et al. IL12 immune therapy clinical trial review: novel strategies for avoiding CRS-associated cytokines. Front Immunol. 2022;13: 952231. https:\/\/doi.org\/10.3389\/fimmu.2022.952231.","journal-title":"Front Immunol"},{"issue":"10","key":"957_CR64","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-14-2085","volume":"21","author":"L Zhang","year":"2015","unstructured":"Zhang L, et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin Cancer Res. 2015;21(10):2278\u201388. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2085.","journal-title":"Clin Cancer Res"},{"key":"957_CR65","doi-asserted-by":"publisher","first-page":"A452","DOI":"10.1136\/jitc-2023-SITC2023.0403","volume-title":"403 Tumor-infiltrating lymphocytes (TIL) with inducible and membrane-bound IL-12 exhibit superior antitumor activity in vitro. Regular and young investigator award abstracts","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Gilbert N, Innamarato P, Fang J, Yin H. 403 Tumor-infiltrating lymphocytes (TIL) with inducible and membrane-bound IL-12 exhibit superior antitumor activity in vitro. Regular and young investigator award abstracts. London: BMJ Publishing Group Ltd; 2023. p. A452. https:\/\/doi.org\/10.1136\/jitc-2023-SITC2023.0403."},{"key":"957_CR66","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-SITC2021.544","author":"B Gastman","year":"2021","unstructured":"Gastman B, et al. 544 DELTA-1: a global, multicenter phase 2 study of ITIL-168, an unrestricted autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in adult patients with advanced cutaneous melanoma. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2021-SITC2021.544.","journal-title":"J Immunother Cancer"},{"issue":"14","key":"957_CR67","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1158\/1078-0432.CCR-21-4499","volume":"28","author":"ST Levi","year":"2022","unstructured":"Levi ST, et al. Neoantigen identification and response to adoptive cell transfer in anti-PD-1 na\u00efve and experienced patients with metastatic melanoma. Clin Cancer Res. 2022;28(14):3042\u201352. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-4499.","journal-title":"Clin Cancer Res"},{"issue":"12_Suppl.","key":"957_CR68","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1158\/1538-7445.AM2022-563","volume":"82","author":"B Sennino","year":"2022","unstructured":"Sennino B, et al. Abstract 563: circulating tumor-specific T cells preferentially recognize patient-specific mutational neoantigens and infrequently recognize shared cancer driver mutations. Cancer Res. 2022;82(12_Suppl.):563. https:\/\/doi.org\/10.1158\/1538-7445.AM2022-563.","journal-title":"Cancer Res"},{"issue":"13_Suppl.","key":"957_CR69","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1158\/1538-7445.AM2021-1508","volume":"81","author":"M Epstein","year":"2021","unstructured":"Epstein M, et al. Abstract 1508: characterization of a novel clonal neoantigen reactive T cell (cNeT) product through a comprehensive translational research program. Cancer Res. 2021;81(13_Suppl.):1508. https:\/\/doi.org\/10.1158\/1538-7445.AM2021-1508.","journal-title":"Cancer Res"},{"issue":"12_Suppl.","key":"957_CR70","doi-asserted-by":"publisher","first-page":"CT153","DOI":"10.1158\/1538-7445.AM2022-CT153","volume":"82","author":"M Gillison","year":"2022","unstructured":"Gillison M, et al. Abstract CT153: TiTAN: a phase 1 study of GEN-011, a neoantigen-targeted peripheral blood-derived T cell therapy with broad neoantigen targeting. Cancer Res. 2022;82(12_Suppl.):CT153. https:\/\/doi.org\/10.1158\/1538-7445.AM2022-CT153.","journal-title":"Cancer Res"},{"issue":"15_Suppl.","key":"957_CR71","doi-asserted-by":"publisher","first-page":"TPS3151","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS3151","volume":"38","author":"B Chmielowski","year":"2020","unstructured":"Chmielowski B, et al. A phase Ia\/Ib, open-label first-in-human study of the safety, tolerability, and feasibility of gene-edited autologous NeoTCR-T cells (NeoTCR-P1) administered to patients with locally advanced or metastatic solid tumors. J Clin Oncol. 2020;38(15_Suppl.):TPS3151. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.TPS3151.","journal-title":"J Clin Oncol"},{"key":"957_CR72","unstructured":"Iovance Biotherapeutics. AKT inhibition during ex vivo TIL expansion enhances cytokine production and function while increasing the population of less differentiated (CD39-CD69-) CD8+T-cells. https:\/\/www.iovance.com\/uploads\/Iovance_ESMO-IO-2021_AKTi-TIL-Expansion.pdf. Accessed 10 Jan 2025."},{"issue":"2","key":"957_CR73","first-page":"454","volume":"9","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, et al. Decitabine treatment sensitizes tumor cells to T-cell-mediated cytotoxicity in patients with myelodysplastic syndromes. Am J Transl Res. 2017;9(2):454\u201365.","journal-title":"Am J Transl Res."},{"issue":"5","key":"957_CR74","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1172\/JCI73639","volume":"124","author":"A Gros","year":"2014","unstructured":"Gros A, et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014;124(5):2246\u201359. https:\/\/doi.org\/10.1172\/JCI73639.","journal-title":"J Clin Invest"},{"issue":"1","key":"957_CR75","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1158\/1078-0432.CCR-13-0945","volume":"20","author":"Q Ye","year":"2014","unstructured":"Ye Q, et al. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res. 2014;20(1):44\u201355. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0945.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"957_CR76","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1158\/1078-0432.CCR-06-1905","volume":"13","author":"MO Butler","year":"2008","unstructured":"Butler MO, et al. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res. 2008;13(6):1857\u201367. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1905.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"957_CR77","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jcyt.2018.11.004","volume":"21","author":"EL Hopewell","year":"2019","unstructured":"Hopewell EL, Cox C, Pilon-Thomas S, Kelley LL. Tumor infiltrating lymphocytes streamlining a complex manufacturing process. Cytotherapy. 2019;21(3):307\u201314. https:\/\/doi.org\/10.1016\/j.jcyt.2018.11.004.","journal-title":"Cytotherapy"},{"key":"957_CR78","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-SITC2023.0747","author":"Y Samhouri","year":"2023","unstructured":"Samhouri Y, et al. 747 Phase 1 trial of LYL845, an autologous tumor-infiltrating lymphocyte (TIL) therapy enhanced with epigenetic reprogramming, for the treatment of advanced solid tumors. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2023-SITC2023.0747.","journal-title":"J Immunother Cancer"},{"key":"957_CR79","unstructured":"ProQuest. 199 Potent T cell costimulation mediated by a novel costimulatory antigen receptor (CoStAR) with dual CD28\/CD40 signaling domains to improve adoptive cell therapies. https:\/\/www.proquest.com\/openview\/1c4740d64aa05538a1914c13b6f0e40c\/1?pq-origsite=gscholar&cbl=2040222. Accessed 8 Jan 2025."},{"issue":"16_Suppl.","key":"957_CR80","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1200\/JCO.2022.40.16_suppl.2535","volume":"40","author":"OR Moon","year":"2022","unstructured":"Moon OR, et al. Antitumor activity of T cells expressing a novel anti-folate receptor alpha (FOLR1) costimulatory antigen receptor (CoStAR) in a human xenograft murine solid tumor model and implications for in-human studies. J Clin Oncol. 2022;40(16_Suppl.):2535. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.2535.","journal-title":"J Clin Oncol"},{"key":"957_CR81","doi-asserted-by":"publisher","first-page":"S704","DOI":"10.1016\/j.annonc.2020.08.1140","volume":"31","author":"M Sharma","year":"2020","unstructured":"Sharma M, et al. 1020O A phase I, first-in-human, open-label, dose escalation study of MGD019, an investigational bispecific PD-1 x CTLA-4 DART\u00ae molecule in patients with advanced solid tumours. Ann Oncol. 2020;31:S704\u20135. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.1140.","journal-title":"Ann Oncol"},{"key":"957_CR82","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.omto.2022.01.004","volume":"24","author":"CA Chamberlain","year":"2022","unstructured":"Chamberlain CA, Bennett EP, Kverneland AH, Svane IM, Donia M, Met \u00d6. Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy. Mol Ther Oncolytics. 2022;24:417\u201328. https:\/\/doi.org\/10.1016\/j.omto.2022.01.004.","journal-title":"Mol Ther Oncolytics."},{"key":"957_CR83","unstructured":"Iovance Biotherapeutics. Genetic modification of Iovance\u2019s TIL through TALEN\u00ae-mediated knockout of PD-1 as a strategy to empower TIL therapy for cancer. https:\/\/www.iovance.com\/uploads\/IovanceBio-ESMO_Poster_1_KritR-v14_20200831a.pdf. Accessed 8 Jan 2025."},{"key":"957_CR84","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-SITC2022.0783","author":"A Betof","year":"2022","unstructured":"Betof A, et al. 783 Trial in progress: a phase 1\/2 open-label study (IOV-GM1\u2013201) of TALEN-mediated PD-1-inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2022-SITC2022.0783.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"957_CR85","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1038\/s41467-018-04013-1","volume":"9","author":"NPD Liau","year":"2018","unstructured":"Liau NPD, et al. The molecular basis of JAK\/STAT inhibition by SOCS1. Nat Commun. 2018;9(1):1558. https:\/\/doi.org\/10.1038\/s41467-018-04013-1.","journal-title":"Nat Commun"},{"key":"957_CR86","first-page":"A215","volume-title":"204 KSQ-004: unbiased pair-wise discovery of SOCS1 and Regnase-1 as the top CRISPR\/Cas9 dual-edit combination enhancing in vivo TIL potency against solid tumors. Regular and young investigator award abstracts","author":"K Wong","year":"2021","unstructured":"Wong K, et al. 204 KSQ-004: unbiased pair-wise discovery of SOCS1 and Regnase-1 as the top CRISPR\/Cas9 dual-edit combination enhancing in vivo TIL potency against solid tumors. Regular and young investigator award abstracts. London: BMJ Publishing Group Ltd; 2021. p. A215."},{"issue":"10","key":"957_CR87","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.medj.2022.07.008","volume":"3","author":"DC Palmer","year":"2022","unstructured":"Palmer DC, et al. Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade. Med. 2022;3(10):682-704.e8. https:\/\/doi.org\/10.1016\/j.medj.2022.07.008.","journal-title":"Med"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00957-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00957-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00957-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T20:03:32Z","timestamp":1757966612000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00957-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":87,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["957"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00957-5","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"assertion":[{"value":"24 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Katy K. Tsai has received consulting honoraria from BMS and Regeneron and institutional research funding from ABM Therapeutics, AstraZeneca, BioAtla, BMS, Genentech, Georgiamune, Ideaya Biosciences, Innovent, OnKure, Pfizer, Replimune, and Regeneron. Krishna V. Komanduri has provided ad hoc consulting for BMS, Cargo Therapeutics, CRISPR Therapeutics, Genentech\/Roche, Incyte, Iovance\u00a0and Sanofi and is a scientific advisory board member for Aegle Therapeutics and CellChorus.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data sharing is not applicable to this review article as no new data were created or analyzed.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Both K.K.T. and K.V.K. contributed to the conception, writing and editing of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}